Braun Stacey Associates Inc. Has $10.88 Million Holdings in Insulet Corporation $PODD

Braun Stacey Associates Inc. lessened its position in Insulet Corporation (NASDAQ:PODD) by 7.1% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 51,858 shares of the medical instruments supplier’s stock after selling 3,987 shares during the quarter. Braun Stacey Associates Inc. owned approximately 0.07% of Insulet worth $10,882,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Larson Financial Group LLC grew its position in Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Insulet in the fourth quarter valued at $26,000. Elyxium Wealth LLC acquired a new stake in shares of Insulet in the fourth quarter worth $28,000. DV Equities LLC acquired a new stake in shares of Insulet in the fourth quarter worth $28,000. Finally, MV Capital Management Inc. acquired a new stake in shares of Insulet in the fourth quarter worth $29,000.

Analyst Ratings Changes

PODD has been the topic of several recent analyst reports. Evercore dropped their price target on Insulet from $240.00 to $200.00 in a research report on Thursday, May 7th. Rothschild & Co Redburn restated a “neutral” rating and set a $220.00 price objective (down from $380.00) on shares of Insulet in a research report on Friday, April 24th. Stifel Nicolaus lowered their target price on Insulet from $350.00 to $250.00 in a research note on Thursday, May 7th. Citigroup lowered their target price on Insulet from $175.00 to $165.00 and set a “neutral” rating on the stock in a research note on Thursday, May 28th. Finally, JPMorgan Chase & Co. dropped their target price on Insulet from $340.00 to $275.00 and set an “overweight” rating on the stock in a report on Thursday, May 7th. Twenty-two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $238.67.

Insulet Trading Up 2.9%

NASDAQ PODD opened at $158.25 on Friday. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. Insulet Corporation has a 1-year low of $138.79 and a 1-year high of $354.88. The firm’s fifty day simple moving average is $159.09 and its 200-day simple moving average is $220.64. The company has a market capitalization of $10.96 billion, a PE ratio of 36.80, a price-to-earnings-growth ratio of 1.10 and a beta of 1.13.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. During the same quarter last year, the firm earned $1.02 earnings per share. The business’s revenue for the quarter was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, sell-side analysts anticipate that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

Insider Buying and Selling at Insulet

In other news, Director Timothy C. Stonesifer purchased 2,790 shares of Insulet stock in a transaction dated Wednesday, June 3rd. The stock was acquired at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the acquisition, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.36% of the stock is owned by company insiders.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.